Chemotargets SL was founded in March 2006 as a spin-off from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM, a leading academic center of excellence based in Barcelona. 

Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new methods generated at Dr. Mestres’ lab.

Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency and safety.

Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.

Since May 2017, Prous Institute for Biomedical Research does strategic investment in Chemotargets SL  which allows CLARITYproduct development to be accelerated and new capabilities to be acquired in order to support the company’s vision and cover the customers needs.